73 related articles for article (PubMed ID: 20480629)
1. Prevention. HAART expansion leads to drop in new infections among infection drug users.
AIDS Policy Law; 2010 Mar; 25(4):1. PubMed ID: 20480629
[No Abstract] [Full Text] [Related]
2. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004.
Donoghoe MC; Bollerup AR; Lazarus JV; Nielsen S; Matic S
Int J Drug Policy; 2007 Aug; 18(4):271-80. PubMed ID: 17689375
[TBL] [Abstract][Full Text] [Related]
3. Mortality among urban drug users and the impact of highly active antiretroviral therapy.
Celentano DD
Clin Infect Dis; 2005 Sep; 41(6):873-4. PubMed ID: 16107988
[No Abstract] [Full Text] [Related]
4. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
5. HIV infection in IVDUs decreases with expanded HIV treatment coverage.
AIDS Patient Care STDS; 2010 Apr; 24(4):266. PubMed ID: 20405530
[No Abstract] [Full Text] [Related]
6. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
7. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
8. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
[TBL] [Abstract][Full Text] [Related]
9. Universal access to HIV/AIDS treatment for injecting drug users: keeping the promise.
Ball AL
Int J Drug Policy; 2007 Aug; 18(4):241-5. PubMed ID: 17689371
[No Abstract] [Full Text] [Related]
10. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
11. Directly observed antiretroviral therapy for injection drug users with HIV infection.
Clarke S; Keenan E; Ryan M; Barry M; Mulcahy F
AIDS Read; 2002 Jul; 12(7):305-7, 312-6. PubMed ID: 12161852
[TBL] [Abstract][Full Text] [Related]
12. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
[TBL] [Abstract][Full Text] [Related]
13. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
14. Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response.
Fardet L; Mary-Krause M; Heard I; Partisani M; Costagliola D;
HIV Med; 2006 Nov; 7(8):520-9. PubMed ID: 17105511
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.
Smit C; Lindenburg K; Geskus RB; Brinkman K; Coutinho RA; Prins M
Addiction; 2006 Mar; 101(3):433-40. PubMed ID: 16499516
[TBL] [Abstract][Full Text] [Related]
16. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
17. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
[TBL] [Abstract][Full Text] [Related]
18. Sexual risk behavior in HIV-infected injection drug users.
Battegay M; Bucher HC; Vernazza P
Clin Infect Dis; 2004 Apr; 38(8):1175-7. PubMed ID: 15095225
[No Abstract] [Full Text] [Related]
19. A review of barriers and facilitators of HIV treatment among injection drug users.
Wood E; Kerr T; Tyndall MW; Montaner JS
AIDS; 2008 Jul; 22(11):1247-56. PubMed ID: 18580603
[TBL] [Abstract][Full Text] [Related]
20. Highly active antiretroviral therapy for injection drug users: physician-recommended strategies for enhanced adherence.
Vassilev ZP; Hagan H
Antivir Ther; 2004 Jun; 9(3):461. PubMed ID: 15259910
[No Abstract] [Full Text] [Related]
[Next] [New Search]
